Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06567080
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-15
Brief Title:
JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open Label Single Arm Study to Evaluate JWCAR201 Treating B Cell Driven Hematology Malignancy and Autoimmune Diseases
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
JWCAR201 is a CD19CD20 CAR-T product This trial is intended to evaluate the safety PKPD and efficacy of JWCAR201 in patients with B cell driven hematology malignancy and autoimmune diseases
Detailed Description:
JWCAR201 is a CD19CD20 CAR-T product By targeting both CD19 and CD20 it is expected to overcome some limitations with CD19 or CD20 single target products In this study patients with B cell driven hematology malignancy and autoimmune diseases will be enrolled to receive JWCAR201 PKPD properties and preliminary efficacy and safety will be evaluated Each subject will receive JWCAR201 once and is followed up for up to 2 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None